RNA Interference Drug Delivery Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on RNA Interference Drug Delivery Market 

5.1. COVID-19 Landscape: RNA Interference Drug Delivery Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global RNA Interference Drug Delivery Market, By Technology

8.1. RNA Interference Drug Delivery Market, by Technology

8.1.1. siRNA (Small Interfering RNA)

8.1.1.1. Market Revenue and Forecast  

8.1.2. miRNA (MicroRNA)

8.1.2.1. Market Revenue and Forecast  

8.1.3. shRNA (Short Hairpin RNA)

8.1.3.1. Market Revenue and Forecast  

8.1.4. Others

8.1.4.1. Market Revenue and Forecast  

Chapter 9. Global RNA Interference Drug Delivery Market, By Delivery System

9.1. RNA Interference Drug Delivery Market, by Delivery System

9.1.1. Lipid Nanoparticles (LNPs)

9.1.1.1. Market Revenue and Forecast  

9.1.2. Polymeric Nanoparticles

9.1.2.1. Market Revenue and Forecast  

9.1.3. Exosomes

9.1.3.1. Market Revenue and Forecast  

9.1.4. Others

9.1.4.1. Market Revenue and Forecast  

Chapter 10. Global RNA Interference Drug Delivery Market, By Route of Administration

10.1. RNA Interference Drug Delivery Market, by Route of Administration

10.1.1. Intravenous

10.1.1.1. Market Revenue and Forecast  

10.1.2. Subcutaneous

10.1.2.1. Market Revenue and Forecast  

10.1.3. Intranasal

10.1.3.1. Market Revenue and Forecast  

10.1.4. Others

10.1.4.1. Market Revenue and Forecast  

Chapter 11. Global RNA Interference Drug Delivery Market, By Target Disease

11.1. RNA Interference Drug Delivery Market, by Target Disease

11.1.1. Cancer

11.1.1.1. Market Revenue and Forecast  

11.1.2. Genetic Disorders

11.1.2.1. Market Revenue and Forecast  

11.1.3. Viral Infections

11.1.3.1. Market Revenue and Forecast  

11.1.4. Metabolic Diseases

11.1.4.1. Market Revenue and Forecast  

11.1.5. Others

11.1.5.1. Market Revenue and Forecast  

Chapter 12. Global RNA Interference Drug Delivery Market, By Target Tissue

12.1. RNA Interference Drug Delivery Market, by Target Tissue

12.1.1. Liver

12.1.1.1. Market Revenue and Forecast  

12.1.2. Lungs

12.1.2.1. Market Revenue and Forecast  

12.1.3. Brain

12.1.3.1. Market Revenue and Forecast  

12.1.4. Heart

12.1.4.1. Market Revenue and Forecast  

12.1.5. Others

12.1.5.1. Market Revenue and Forecast  

Chapter 13. Global RNA Interference Drug Delivery Market, By End-User

13.1. RNA Interference Drug Delivery Market, by End-User

13.1.1. Pharmaceutical Companies

13.1.1.1. Market Revenue and Forecast  

13.1.2. Biotechnology Companies

13.1.2.1. Market Revenue and Forecast  

13.1.3. Academic and Research Institutions

13.1.3.1. Market Revenue and Forecast  

13.1.4. Hospitals and Clinics

13.1.4.1. Market Revenue and Forecast  

Chapter 14. Global RNA Interference Drug Delivery Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Technology  

14.1.2. Market Revenue and Forecast, by Delivery System  

14.1.3. Market Revenue and Forecast, by Route of Administration  

14.1.4. Market Revenue and Forecast, by Target Disease  

14.1.5. Market Revenue and Forecast, by Target Tissue  

14.1.6. Market Revenue and Forecast, by End-User  

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Technology  

14.1.7.2. Market Revenue and Forecast, by Delivery System  

14.1.7.3. Market Revenue and Forecast, by Route of Administration  

14.1.7.4. Market Revenue and Forecast, by Target Disease  

14.1.8. Market Revenue and Forecast, by Target Tissue  

14.1.8.1. Market Revenue and Forecast, by End-User   

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Technology  

14.1.9.2. Market Revenue and Forecast, by Delivery System  

14.1.9.3. Market Revenue and Forecast, by Route of Administration  

14.1.9.4. Market Revenue and Forecast, by Target Disease  

14.1.10. Market Revenue and Forecast, by Target Tissue  

14.1.11. Market Revenue and Forecast, by End-User  

14.2. Europe

14.2.1. Market Revenue and Forecast, by Technology  

14.2.2. Market Revenue and Forecast, by Delivery System  

14.2.3. Market Revenue and Forecast, by Route of Administration  

14.2.4. Market Revenue and Forecast, by Target Disease   

14.2.5. Market Revenue and Forecast, by Target Tissue  

14.2.6. Market Revenue and Forecast, by End-User  

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Technology  

14.2.8.2. Market Revenue and Forecast, by Delivery System  

14.2.8.3. Market Revenue and Forecast, by Route of Administration  

14.2.9. Market Revenue and Forecast, by Target Disease   

14.2.10. Market Revenue and Forecast, by Target Tissue  

14.2.10.1. Market Revenue and Forecast, by End-User   

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Technology  

14.2.11.2. Market Revenue and Forecast, by Delivery System  

14.2.11.3. Market Revenue and Forecast, by Route of Administration  

14.2.12. Market Revenue and Forecast, by Target Disease  

14.2.13. Market Revenue and Forecast, by Target Tissue  

14.2.14. Market Revenue and Forecast, by End-User  

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Technology  

14.2.15.2. Market Revenue and Forecast, by Delivery System  

14.2.15.3. Market Revenue and Forecast, by Route of Administration  

14.2.15.4. Market Revenue and Forecast, by Target Disease  

14.2.16. Market Revenue and Forecast, by Target Tissue  

14.2.16.1. Market Revenue and Forecast, by End-User  

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Technology  

14.2.17.2. Market Revenue and Forecast, by Delivery System  

14.2.17.3. Market Revenue and Forecast, by Route of Administration  

14.2.17.4. Market Revenue and Forecast, by Target Disease  

14.2.18. Market Revenue and Forecast, by Target Tissue  

14.2.18.1. Market Revenue and Forecast, by End-User  

14.3. APAC

14.3.1. Market Revenue and Forecast, by Technology  

14.3.2. Market Revenue and Forecast, by Delivery System  

14.3.3. Market Revenue and Forecast, by Route of Administration  

14.3.4. Market Revenue and Forecast, by Target Disease  

14.3.5. Market Revenue and Forecast, by Target Tissue  

14.3.6. Market Revenue and Forecast, by End-User  

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Technology  

14.3.7.2. Market Revenue and Forecast, by Delivery System  

14.3.7.3. Market Revenue and Forecast, by Route of Administration  

14.3.7.4. Market Revenue and Forecast, by Target Disease  

14.3.8. Market Revenue and Forecast, by Target Tissue  

14.3.9. Market Revenue and Forecast, by End-User  

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Technology  

14.3.10.2. Market Revenue and Forecast, by Delivery System  

14.3.10.3. Market Revenue and Forecast, by Route of Administration  

14.3.10.4. Market Revenue and Forecast, by Target Disease  

14.3.11. Market Revenue and Forecast, by Target Tissue  

14.3.11.1. Market Revenue and Forecast, by End-User  

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Technology  

14.3.12.2. Market Revenue and Forecast, by Delivery System  

14.3.12.3. Market Revenue and Forecast, by Route of Administration  

14.3.12.4. Market Revenue and Forecast, by Target Disease  

14.3.12.5. Market Revenue and Forecast, by Target Tissue  

14.3.12.6. Market Revenue and Forecast, by End-User  

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Technology  

14.3.13.2. Market Revenue and Forecast, by Delivery System  

14.3.13.3. Market Revenue and Forecast, by Route of Administration  

14.3.13.4. Market Revenue and Forecast, by Target Disease  

14.3.13.5. Market Revenue and Forecast, by Target Tissue  

14.3.13.6. Market Revenue and Forecast, by End-User  

14.4. MEA

14.4.1. Market Revenue and Forecast, by Technology  

14.4.2. Market Revenue and Forecast, by Delivery System  

14.4.3. Market Revenue and Forecast, by Route of Administration  

14.4.4. Market Revenue and Forecast, by Target Disease  

14.4.5. Market Revenue and Forecast, by Target Tissue  

14.4.6. Market Revenue and Forecast, by End-User  

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Technology  

14.4.7.2. Market Revenue and Forecast, by Delivery System  

14.4.7.3. Market Revenue and Forecast, by Route of Administration  

14.4.7.4. Market Revenue and Forecast, by Target Disease  

14.4.8. Market Revenue and Forecast, by Target Tissue  

14.4.9. Market Revenue and Forecast, by End-User  

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Technology  

14.4.10.2. Market Revenue and Forecast, by Delivery System  

14.4.10.3. Market Revenue and Forecast, by Route of Administration  

14.4.10.4. Market Revenue and Forecast, by Target Disease  

14.4.11. Market Revenue and Forecast, by Target Tissue  

14.4.12. Market Revenue and Forecast, by End-User  

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Technology  

14.4.13.2. Market Revenue and Forecast, by Delivery System  

14.4.13.3. Market Revenue and Forecast, by Route of Administration  

14.4.13.4. Market Revenue and Forecast, by Target Disease  

14.4.13.5. Market Revenue and Forecast, by Target Tissue  

14.4.13.6. Market Revenue and Forecast, by End-User  

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Technology  

14.4.14.2. Market Revenue and Forecast, by Delivery System  

14.4.14.3. Market Revenue and Forecast, by Route of Administration  

14.4.14.4. Market Revenue and Forecast, by Target Disease  

14.4.14.5. Market Revenue and Forecast, by Target Tissue  

14.4.14.6. Market Revenue and Forecast, by End-User  

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Technology  

14.5.2. Market Revenue and Forecast, by Delivery System  

14.5.3. Market Revenue and Forecast, by Route of Administration  

14.5.4. Market Revenue and Forecast, by Target Disease  

14.5.5. Market Revenue and Forecast, by Target Tissue  

14.5.6. Market Revenue and Forecast, by End-User  

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Technology  

14.5.7.2. Market Revenue and Forecast, by Delivery System  

14.5.7.3. Market Revenue and Forecast, by Route of Administration  

14.5.7.4. Market Revenue and Forecast, by Target Disease  

14.5.8. Market Revenue and Forecast, by Target Tissue  

14.5.8.1. Market Revenue and Forecast, by End-User  

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Technology  

14.5.9.2. Market Revenue and Forecast, by Delivery System  

14.5.9.3. Market Revenue and Forecast, by Route of Administration  

14.5.9.4. Market Revenue and Forecast, by Target Disease  

14.5.9.5. Market Revenue and Forecast, by Target Tissue  

14.5.9.6. Market Revenue and Forecast, by End-User  

Chapter 15. Company Profiles

15.1. Ionis Pharmaceuticals

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Moderna, Inc

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Arrowhead Pharmaceuticals

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Arcturus Therapeutics

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Dicerna Pharmaceuticals (Acquired by Novo Nordisk)

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Silence Therapeutics

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Ionis Pharmaceuticals

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. CureVac AG

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. GSK plc

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Sanofi

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms